Obecabtagene autoleucel

欧贝妥基奥仑赛

Report date: 2026/04/28 20:00:22

Base Information

Drug NameObecabtagene autoleucel
Drug Alias NameCD19CAT-41BBZ CAR T-cellsAnti-CD19 CAR T cell therapy(University College London)AUCATZYLAUTO-1AUTO1 +[6] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derived +[4] 
Mechanisms of ActionAnti-CD19T lymphocyte replacementsImmunologic cytotoxicity
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLupus Erythematosus, SystemicLupus NephritisMultiple Sclerosis, Chronic Progressive +[6] 
Global Approved IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/11/08
Country/TerritoryUnited StatesUnited KingdomBrazil +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesUniversity College London
China Registration ClassN/A

Develop Information

Active CompaniesAutolus GmbhAutolus Therapeutics PlcThe University Of Texas MD Anderson Cancer Center +[5] 
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicLupus NephritisMultiple Sclerosis, Chronic Progressive +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBank